Full text is available at the source.
Abstract
The study investigates the relationship between GLP-1 receptor agonist initiation and psychiatric hospitalization in adults with schizophrenia and type 2 diabetes.
- Individuals with schizophrenia often experience ongoing psychotic symptoms despite treatment.
- Schizophrenia is linked to significant metabolic dysregulation.
- The potential psychiatric benefits of GLP-1 receptor agonists alongside their effects on metabolism are currently unclear.
- Comparisons will be made between GLP-1 receptor agonists and other diabetes medications, including DPP-4 inhibitors and SGLT2 inhibitors.
Simplified
GLP-1 Therapies